Awaiting development: Guidance and quality standards

Showing 221 to 230 of 285

Guidance and quality standards awaiting development
Title	Type
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042	Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [TS ID 12095]	Technology appraisal guidance
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]	Technology appraisal guidance
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458	Technology appraisal guidance
Semaglutide for treating type 2 diabetes (ID1450)	Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995	Technology appraisal guidance
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827	Technology appraisal guidance
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147	Technology appraisal guidance
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height TSID 12070	Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]	Technology appraisal guidance